Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis.

Lund AM, Borgwardt L, Cattaneo F, Ardigò D, Geraci S, Gil-Campos M, De Meirleir L, Laroche C, Dolhem P, Cole D, Tylki-Szymanska A, Lopez-Rodriguez M, Guillén-Navarro E, Dali CI, Héron B, Fogh J, Muschol N, Phillips D, Van den Hout JMH, Jones SA, Amraoui Y, Harmatz P, Guffon N

Open source

DOI: 10.1007/s10545-018-0175-2
Published: 2018 Nov
Container: Journal of inherited metabolic disease
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10545-018-0175-2,
  title = {Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis.},
  author = {Lund AM and Borgwardt L and Cattaneo F and Ardigò D and Geraci S and Gil-Campos M and De Meirleir L and Laroche C and Dolhem P and Cole D and Tylki-Szymanska A and Lopez-Rodriguez M and Guillén-Navarro E and Dali CI and Héron B and Fogh J and Muschol N and Phillips D and Van den Hout JMH and Jones SA and Amraoui Y and Harmatz P and Guffon N},
  year = {2018},
  journal = {Journal of inherited metabolic disease},
  doi = {10.1007/s10545-018-0175-2},
  url = {https://doi.org/10.1007/s10545-018-0175-2}
}

RIS

TY  - JOUR
TI  - Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis.
AU  - Lund AM
AU  - Borgwardt L
AU  - Cattaneo F
AU  - Ardigò D
AU  - Geraci S
AU  - Gil-Campos M
AU  - De Meirleir L
AU  - Laroche C
AU  - Dolhem P
AU  - Cole D
AU  - Tylki-Szymanska A
AU  - Lopez-Rodriguez M
AU  - Guillén-Navarro E
AU  - Dali CI
AU  - Héron B
AU  - Fogh J
AU  - Muschol N
AU  - Phillips D
AU  - Van den Hout JMH
AU  - Jones SA
AU  - Amraoui Y
AU  - Harmatz P
AU  - Guffon N
PY  - 2018
JO  - Journal of inherited metabolic disease
DO  - 10.1007/s10545-018-0175-2
UR  - https://doi.org/10.1007/s10545-018-0175-2
ER  -

APA

AM, L., L, B., F, C., D, A., S, G., M, G., L, D. M., C, L., P, D., D, C., A, T., M, L., E, G., CI, D., B, H., J, F., N, M., D, P., JMH, V. D. H., SA, J., Y, A., P, H., & N, G. (2018). Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis.. Journal of inherited metabolic disease. https://doi.org/10.1007/s10545-018-0175-2

Source records

pubmed · retrieved 2026-09-25T18:30:44.377Z